ATE254469T1 - Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten - Google Patents
Verfahren zur verminderung der renalen aufnahme von antikörperfragmentenInfo
- Publication number
- ATE254469T1 ATE254469T1 AT96910422T AT96910422T ATE254469T1 AT E254469 T1 ATE254469 T1 AT E254469T1 AT 96910422 T AT96910422 T AT 96910422T AT 96910422 T AT96910422 T AT 96910422T AT E254469 T1 ATE254469 T1 AT E254469T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody fragments
- reducing renal
- lysine
- renal uptake
- poly
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/407,899 US5843894A (en) | 1995-03-21 | 1995-03-21 | Methods for reduced renal uptake of antibody fragments |
| PCT/US1996/003308 WO1996029087A1 (en) | 1995-03-21 | 1996-03-20 | Methods for reduced renal uptake of antibody fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE254469T1 true ATE254469T1 (de) | 2003-12-15 |
Family
ID=23614010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96910422T ATE254469T1 (de) | 1995-03-21 | 1996-03-20 | Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US5843894A (de) |
| EP (1) | EP0767673B1 (de) |
| JP (1) | JPH10505866A (de) |
| AT (1) | ATE254469T1 (de) |
| CA (1) | CA2190867C (de) |
| DE (1) | DE69630761T2 (de) |
| ES (1) | ES2211951T3 (de) |
| IL (1) | IL117564A (de) |
| WO (1) | WO1996029087A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843894A (en) * | 1995-03-21 | 1998-12-01 | Center For Molecular Medicine And Immunology | Methods for reduced renal uptake of antibody fragments |
| EP1187637A2 (de) * | 1999-06-07 | 2002-03-20 | Center For Molecular Medicine And Immunology | Alpha und beta strahlern angekoppelt zu fragmente im radioimmunotherapie |
| AU6275800A (en) * | 1999-07-16 | 2001-02-05 | Mallinckrodt, Inc. | Inhibition of renal uptake of molecules that are potentially damaging for the kidney |
| EP1862172A1 (de) * | 2006-05-31 | 2007-12-05 | BioSynthema Inc. | Zusammensetzung von einer Aminosäurelösung und Gelatine zur Hemmung renaler Aufnahme |
| WO2013106824A1 (en) * | 2012-01-13 | 2013-07-18 | Board Of Regents, The University Of Texas System | Epherin receptor targeting agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283342A (en) * | 1992-06-09 | 1994-02-01 | Neorx Corporation | Biotinylated small molecules |
| US4701521A (en) * | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
| US5595734A (en) * | 1988-04-06 | 1997-01-21 | Alfacell Corporation | Compositions comprising ONCONASE (tm) and lovastatin |
| ATE136224T1 (de) * | 1989-09-29 | 1996-04-15 | Neorx Corp | Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten |
| US5225180A (en) * | 1991-09-10 | 1993-07-06 | Diatech, Inc. | Technetium-99m labeled somatostatin-derived peptides for imaging |
| US5843894A (en) * | 1995-03-21 | 1998-12-01 | Center For Molecular Medicine And Immunology | Methods for reduced renal uptake of antibody fragments |
| US5840296A (en) * | 1997-10-15 | 1998-11-24 | Raines; Ronald T. | Engineered cytotoxic ribonuclease A |
-
1995
- 1995-03-21 US US08/407,899 patent/US5843894A/en not_active Expired - Lifetime
-
1996
- 1996-03-20 ES ES96910422T patent/ES2211951T3/es not_active Expired - Lifetime
- 1996-03-20 IL IL11756496A patent/IL117564A/xx active IP Right Grant
- 1996-03-20 CA CA002190867A patent/CA2190867C/en not_active Expired - Fee Related
- 1996-03-20 DE DE69630761T patent/DE69630761T2/de not_active Expired - Lifetime
- 1996-03-20 AT AT96910422T patent/ATE254469T1/de not_active IP Right Cessation
- 1996-03-20 WO PCT/US1996/003308 patent/WO1996029087A1/en not_active Ceased
- 1996-03-20 JP JP8528465A patent/JPH10505866A/ja active Pending
- 1996-03-20 EP EP96910422A patent/EP0767673B1/de not_active Expired - Lifetime
-
1998
- 1998-11-30 US US09/200,791 patent/US20020111300A1/en not_active Abandoned
-
2003
- 2003-05-15 US US10/438,219 patent/US20030203836A1/en not_active Abandoned
-
2006
- 2006-01-30 US US11/341,431 patent/US20060182683A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL117564A0 (en) | 1996-07-23 |
| US20060182683A1 (en) | 2006-08-17 |
| US20020111300A1 (en) | 2002-08-15 |
| CA2190867A1 (en) | 1996-09-26 |
| US20030203836A1 (en) | 2003-10-30 |
| IL117564A (en) | 2005-03-20 |
| DE69630761T2 (de) | 2004-09-23 |
| AU700346B2 (en) | 1999-01-07 |
| AU5361696A (en) | 1996-10-08 |
| EP0767673A1 (de) | 1997-04-16 |
| EP0767673B1 (de) | 2003-11-19 |
| EP0767673A4 (de) | 1999-08-04 |
| JPH10505866A (ja) | 1998-06-09 |
| DE69630761D1 (de) | 2003-12-24 |
| WO1996029087A1 (en) | 1996-09-26 |
| CA2190867C (en) | 2009-06-02 |
| ES2211951T3 (es) | 2004-07-16 |
| US5843894A (en) | 1998-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE59904569D1 (de) | Therapeutikum zur unterdrückung von schnarchgeräuschen | |
| BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
| NO985464L (no) | Konsentrert antistoffpreparat | |
| HUT76970A (hu) | Készítmény az érrendszer specifikus koagulálásához | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| HUP9802556A1 (hu) | Eljárás és készítmény kötőszöveti kapcsolódások gyógyítására és helyreállítására | |
| EP0679093A1 (de) | Methode zum überbringen von agenzien an zielzellen. | |
| BR9913645A (pt) | Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20 | |
| EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| PT831882E (pt) | Composicoes de segmentos de fibra de colagenio reconstituido e metodos de preparacao das mesmas | |
| PT1017675E (pt) | Derivados da camtotecina altamente lipofilos | |
| DK1098643T3 (da) | Phenylacetylglutamin, phenylacetylisoglutamin og/eller phenylacetat til behandling af neoplastiske sygdomme | |
| ATE239474T1 (de) | Verwendung von levobupivacain | |
| UA26403A (uk) | Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція | |
| NO971341L (no) | Promoter for reseptor tyrosinkinase TIE | |
| DE69725860D1 (de) | PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN | |
| BR9811861A (pt) | Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh) | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| BR0114110A (pt) | Conjugado de ligação de fibrina/fibrinogênio, kit e método para produzir um depósito de uma substância farmaceuticamente ativa, depósito de uma substância farmaceuticamente ativa, e, método para tratar de um paciente que sofre de um estado patológico | |
| BR0111158A (pt) | Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente | |
| BG101038A (bg) | Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък | |
| DE69631542D1 (de) | Neue geranylgeranylderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen | |
| ATE254469T1 (de) | Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten | |
| PT1007040E (pt) | Utilizacao de fanquinona no tratamento da doenca de alzheimer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |